UNSPSC 51384800: Nonsteroidal anti inflammatory pyridines

Nonsteroidal anti inflammatory drugs made from compounds with a six membered aromatic ring containing nitrogen.

UNSPSC 51384800 Nonsteroidal anti inflammatory pyridines is a Class code, but the recent state and local opportunities tagged under it diverge significantly from the code's nominal pharmaceutical scope. The three most recent solicitations include a Florida county's IFB for naloxone and drug deactivation systems, a Texas state HHS Commission RFI on direct-to-manufacturer prescription programs, and a Minnesota cooperative purchasing RFP for generic multi-source pharmaceuticals and over-the-counter products. The actual work being solicited spans pharmaceutical procurement, drug-safety initiatives, and prescription-benefit program design rather than the specific anti-inflammatory pyridine drug class the code name suggests. Issuing bodies include county public health departments, state health agencies, and multistate cooperative purchasing alliances administering procurement on behalf of participating state and local facilities. The mismatch between the code label and the actual procurement activity suggests the code may be used broadly as a catch-all pharmaceutical classification or that the opportunities are miscoded.

The recent geographic spread includes Florida, Texas, and Minnesota, with the Minnesota MMCAP procurement explicitly spanning multiple participating states including Oregon. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, bid due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 posted April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs without formal evaluation timelines or award amounts. The Minnesota Department of Administration, through MMCAP, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to work with three authorized wholesalers and meet cGMP and DSCSA compliance. Contract values and budget ranges are not disclosed across these solicitations. The code shows substantive state and local activity, but buyers should verify whether their product or service scope aligns with the actual pharmaceutical procurement patterns rather than the pyridine-specific code name.